TACE治疗肝癌合并PVTT的研究进展
Progress of TACE for Hepatocellular Carcinoma Combined with PVTT
DOI: 10.12677/ACM.2023.132195, PDF,   
作者: 齐梦剑：青海大学研究生院，青海 西宁；青海大学附属医院肝胆胰外科，青海 西宁；王志鑫*：青海大学研究生院，青海 西宁
关键词: 肝细胞癌；门静脉癌栓；TACE；治疗；Hepatocellular Carcinoma； Portal Vein Tumor Thrombus； TACE； Treatment
摘要: 肝癌是常见的恶性肿瘤之一。肝细胞癌(HCC)是最常见的病理分型，乙型肝炎病毒是HCC发展的最显著风险因素。晚期肝细胞癌易发生血管侵犯，以门静脉侵犯最为多见(PVTT)，PVTT患者预后极差，死亡率极高。TACE广泛应用于中晚期肝细胞癌，目前有着大量的单独TACE或TACE联合其他方法治疗门静脉癌栓的文章。本文对肝细胞癌合并PVTT的TACE治疗进展作一综述。
Abstract: Hepatocellular carcinoma (HCC) is one of the common malignancies. Hepatocellular carcinoma is the most common pathological strain, and hepatitis B virus is the most significant risk factor for HCC development. Advanced hepatocellular carcinoma is prone to vascular invasion, most commonly portal vein tumor thrombus (PVTT), and patients with PVTT have an extremely poor prognosis and high mortality rate. TACE is widely used in intermediate and advanced hepatocellular carcinoma, and there are numerous articles on TACE alone or TACE combined with other methods to treat por-tal vein thrombosis. This article reviews the progress of TACE treatment for hepatocellular carci-noma combined with PVTT.
文章引用：齐梦剑, 王志鑫. TACE治疗肝癌合并PVTT的研究进展[J]. 临床医学进展, 2023, 13(2): 1416-1420. https://doi.org/10.12677/ACM.2023.132195

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Akinyemiju, T., Abera, S., Ahmed, M., et al. (2017) The Burden of Pri-mary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncology, 3, 1683-1691.
[3] Estes, C., Razavi, H., Loomba, R., et al. (2018) Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology, 67, 123-133. [Google Scholar] [CrossRef] [PubMed]
[4] Cabibbo, G., Enea, M., Atta-nasio, M., et al. (2010) A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepa-tocellular Carcinoma. Hepatology, 51, 1274-1283. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, Z.M., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, Z., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. [Google Scholar] [CrossRef] [PubMed]
[7] Ikai, I., Yamamoto, Y., Yamamoto, N., Terajima, H., et al. (2003) Results of Hepatic Resection for Hepatocellular Carcinoma Invading Major Portal and/or Hepatic Veins. Surgical Oncology Clinics of North America, 12, 65-75. [Google Scholar] [CrossRef] 
[8] Cheng, S.Q., et al. (2007) Tumor Thrombus Types Influence the Prognosis of Hepatocellular Carcinoma with the Tumor Thrombi in the Portal Vein. Hepatogastroenterology, 54, 499-502.
[9] Chung, G.E., Lee, J.H., Kim, H.Y., et al. (2011) Transarterial Chemoembolization Can Be Safely Per-formed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology, 258, 627-634. [Google Scholar] [CrossRef] [PubMed]
[10] Luo, J., Guo, R.P., Lai, E.C., et al. (2011) Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Annals of Surgical Oncology, 18, 413-420. [Google Scholar] [CrossRef] [PubMed]
[11] Huo, Y.R. and Eslick, G.D. (2015) Transcatheter Arterial Che-moembolization plus Radiotherapy Compared with Chemoembolization Alone for Hepatocellular Carcinoma: A System-atic Review and Meta-Analysis. JAMA Oncology, 1, 756-765. [Google Scholar] [CrossRef] [PubMed]
[12] Li, M.F., Leung, H.W., Chan, A.L., et al. (2018) Network Meta-Analysis of Treatment Regimens for Inoperable Advanced Hepatocellular Carcinoma with Portal Vein Invasion. Therapeutics and Clinical Risk Management, 14, 1157-1168. [Google Scholar] [CrossRef] 
[13] Liu, B.J., Gao, S., Zhu, X., et al. (2021) Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. BioMed Research In-ternational, 2021, Article ID: 6670367. [Google Scholar] [CrossRef] [PubMed]
[14] Guo, L., Wei, X., Feng, S., et al. (2022) Radiotherapy Prior to or after Transcatheter Arterial Chemoembolization for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized Controlled Trial. Hepatology International, 16, 1368-1378. [Google Scholar] [CrossRef] [PubMed]
[15] Huang, M., Lin, Q., Wang, H., et al. (2016) Survival Benefit of Chemoembolization plus Iodine125 Seed Implantation in Unresectable Hepatitis B-Related Hepatocellular Carcinoma with PVTT: A Retrospective Matched Cohort Study. European Radiology, 26, 3428-3436. [Google Scholar] [CrossRef] [PubMed]
[16] Zhu, K., Chen, J., Lai, L., et al. (2014) Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenib—A Ret-rospective Controlled Study. Radiology, 272, 284-293. [Google Scholar] [CrossRef] [PubMed]
[17] Ding, X., Sun, W., Li, W., et al. (2021) Transarterial Chemoemboli-zation plus Lenvatinib versus Transarterial Chemoembolization plus Sorafenib as First-Line Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Prospective Randomized Study. Cancer, 127, 3782-3793. [Google Scholar] [CrossRef] [PubMed]
[18] Fan, W., Yuan, G., Fan, H., et al. (2019) Apatinib Combined with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multi-center Retrospective Study. Clinical Therapeutics, 41, 1463-1476. [Google Scholar] [CrossRef] [PubMed]

为你推荐